Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Aberrant p53 fuels macrophage immunoregulatory polarization and refractory clinical outcome in urothelial carcinoma.

Journal for immunotherapy of cancer - 20 May 2026

Ding Yawei, Jin Kaifeng, Su Xiaohe, Zhang Lingkai, Liu Zhaopei, Sun Jiaxing, Wu Yuzhen, Shi Jinming, Zeng Han, Liu Hailong, Zhu Yu, Xu Le, Wang Zewei, Chang Yuan, Zhang Weijuan, Xu Jiejie

Abstract excerpt

BACKGROUND: Urothelial carcinoma (UC) exhibits extensive infiltration of tumor-associated macrophages (TAMs). As the most frequently altered gene in UC, TP53 is recognized not only as a guardian of genomic integrity, but also as a potential architect of the tumor immune microenvironment (TIME). However, how aberrant p53 status, comprising TP53 mutation (TP53 Mut) and p53 abnormal expression (p53Abn), correlates...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CXCL9 gene
Share to SPP1 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Macrophages

Share to Mutation

Share to Tumor-Associated Macrophages

Share to Tumor Microenvironment

Share to Tumor Suppressor Protein p53

Share to Urinary Bladder Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 42161402
DOI: 10.1136/jitc-2025-014408
PMCID: PMC13202007

Genes

TP53
SPP1
CD4
CD44
CXCL10
CXCL11
CXCL9
IDO1
INHBA
MARCO
SLC2A1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Aberrant p53 fuels macrophage immunoregulatory polarization and refractory clinical outcome in urothelial carcinoma.PMID 42161402Read ↗

TP53-related signature for predicting prognosis and tumor microenvironment characteristics in bladder cancer: A multi-omics studySemantic proximity Read ↗

SnapShot: TP53 status and macrophages infiltration in TCGA-analyzed tumors.Semantic proximity Read ↗

A TP53-Associated Immune Prognostic Signature for the Prediction of Overall Survival and Therapeutic Responses in Muscle-Invasive Bladder Cancer.Semantic proximity Read ↗

Single-cell profiling reveals systemic immune reprogramming in muscle-invasive urothelial carcinomaSemantic proximity Read ↗

Macrophage correlates with immunophenotype and predicts anti-PD-L1 response of urothelial cancer.Semantic proximity Read ↗

Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53 co-alteration in pancreatic cancer.Semantic proximity Read ↗

Distinct Mechanisms of Innate and Adaptive Immune Regulation Underlie Poor Oncologic Outcomes Associated with <i>KRAS-TP53</i> Co-Alteration in Pancreatic CancerSemantic proximity Read ↗

The impact of p53 mutation on tumor immune evasion: mechanistic insights and clinical implications.Semantic proximity Read ↗

Myeloid Cell–associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA SequencingSemantic proximity Read ↗

Myeloid cell-associated resistance to PD-1/PD-L1 blockade in urothelial cancer revealed through bulk and single-cell RNA sequencingSemantic proximity Read ↗

Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246.Semantic proximity Read ↗

TERT promoter mutations or protein overexpression define an aggressive subset with favourable immunotherapeutic response in advanced urothelial carcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.